
nQ Medical provides passive, continuous monitoring to detect and track neurocognitive and neuromotor decline earlier than standard clinical assessments. It captures typing and touchscreen kinematics from everyday personal devices and applies AI-driven computational biomarkers to derive objective measures of functional change. The company operates as a digital therapeutics and neurotechnology solution for remote disease progression monitoring and therapeutic measurement in clinical and research settings. Its technology requires no active tasks from users and emphasizes low-cost, at-home data collection compared with traditional clinical instruments. nQ positions its platform for use in clinical practice and trials to support early detection, longitudinal monitoring, and measurement of treatment impact.

nQ Medical provides passive, continuous monitoring to detect and track neurocognitive and neuromotor decline earlier than standard clinical assessments. It captures typing and touchscreen kinematics from everyday personal devices and applies AI-driven computational biomarkers to derive objective measures of functional change. The company operates as a digital therapeutics and neurotechnology solution for remote disease progression monitoring and therapeutic measurement in clinical and research settings. Its technology requires no active tasks from users and emphasizes low-cost, at-home data collection compared with traditional clinical instruments. nQ positions its platform for use in clinical practice and trials to support early detection, longitudinal monitoring, and measurement of treatment impact.
Founded: August 2016 — Cambridge, Massachusetts
Product: Passive, continuous AI-based digital biomarkers derived from everyday typing and touchscreen interactions
Use cases: Early detection and longitudinal remote monitoring of neurocognitive and neuromotor decline; clinical-trial measurement
Funding: Total reported funding 4,450,000 USD; last Seed round announced 2021-11-16
Investors: GSK NEXT, DigiTx Partners, PharmStars, XLerateHealth, Bob Saunders (plus EIT Health support entry)
Detection and remote longitudinal monitoring of neurocognitive and neuromotor decline
2016
Biotechnology
Funding round page references a MassDevice report of $1.5M
Listed as most recent Seed round
€10.0k
Dealroom support program entry
“Backed by GSK NEXT, DigiTx Partners, PharmStars, XLerateHealth and investor Bob Saunders; received EIT Health support”